Returns
Every filed return on the register. Filter, then open any return on lobbying.ie to read it in full.
Showing returns filed by Hanover Media Strategy Limited .
Filed returns
40
match these filters
| Period | Registrant | Policy area | Subject, as filed | Officials named | Link |
|---|---|---|---|---|---|
| Jan–Apr 2026 | Hanover Media Strategy Limited | Health | Discussion of proposed Early Access Programme for innovative oncology medicines. (Public policy or programme) | 3 | On lobbying.ie |
| Sep–Dec 2025 | Hanover Media Strategy Limited | Health | Information on a Proposal for an Early Access Programme for Innovative Oncology Medicines (Public policy or programme) | 6 | On lobbying.ie |
| May–Aug 2025 | Hanover Media Strategy Limited | Health | Sharing proposal for early access pilot programme (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Hanover Media Strategy Limited | Health | Request for information on engagement approach (Public policy or programme) | 1 | On lobbying.ie |
| May–Aug 2025 | Hanover Media Strategy Limited | Sports and Recreation | AV Room Briefing Event to discuss the ongoing policy challenges in the sports sector (Public policy or programme) | 62 | On lobbying.ie |
| May–Aug 2025 | Hanover Media Strategy Limited | Children and Youth Affairs | AV Room Briefing Event to discuss the ongoing crises facing the early years and childcare sector (Public policy or programme) | 29 | On lobbying.ie |
| Jan–Apr 2025 | Hanover Media Strategy Limited | Health | An introduction to AstraZeneca Ireland (Public policy or programme) | 2 | On lobbying.ie |
| Jan–Apr 2025 | Hanover Media Strategy Limited | Health | Congratulatory letter to the new Minister for Health (Public policy or programme) | 2 | On lobbying.ie |
| Sep–Dec 2024 | Hanover Media Strategy Limited | Health | Life Sciences Strategy for Ireland (Public policy or programme) | 10 | On lobbying.ie |
| Sep–Dec 2024 | Hanover Media Strategy Limited | Health | To share information on the level of vaccine protection for the over 65s population in Ireland (Public policy or programme) | 5 | On lobbying.ie |
| Jan–Apr 2024 | Hanover Media Strategy Limited | Health | Invitation to a roundtable discussion on the challenges and pressures posed by influenza on the Irish health system, with a particular focus on the over 65s population. (Public policy or programme) | 15 | On lobbying.ie |
| Jan–Apr 2024 | Hanover Media Strategy Limited | Health | Engagement with members of the health committee in advance of debate on rare diseases (Public policy or programme) | 15 | On lobbying.ie |
| Sep–Dec 2023 | Hanover Media Strategy Limited | Health | Influenza vaccination campaign (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2023 | Hanover Media Strategy Limited | Health | Influenza vaccination campaign. (Public policy or programme) | 2 | On lobbying.ie |
| May–Aug 2023 | Hanover Media Strategy Limited | Health | Discussion on the level of influenza vaccine protection for the over 65 population in Ireland. (Public policy or programme) | 23 | On lobbying.ie |
| Jan–Apr 2022 | Hanover Media Strategy Limited | Health | Introducing Horizon and its presence in Ireland (Public policy or programme) | 16 | On lobbying.ie |
| Sep–Dec 2021 | Hanover Media Strategy Limited | Health | Partnership for Health System Sustainability and Resilience (Public policy or programme) | 4 | On lobbying.ie |
| Sep–Dec 2021 | Hanover Media Strategy Limited | Health | Update on AstraZeneca COVID-19 vaccine and therapies (Public policy or programme) | 5 | On lobbying.ie |
| May–Aug 2021 | Hanover Media Strategy Limited | Health | Update on COVID-19 Vaccine AstraZeneca (Public policy or programme) | 8 | On lobbying.ie |
| May–Aug 2021 | Hanover Media Strategy Limited | Health | Medicines Access for Irish patients with rare diseases (Legislation) | 1 | On lobbying.ie |
| May–Aug 2021 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 9 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Update on COVID-19 Vaccine AstraZeneca (Public policy or programme) | 15 | On lobbying.ie |
| Jan–Apr 2021 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 15 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Centralised Services for Rare Disease Medicines (Public policy or programme) | 1 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 14 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Transport | Cost of Motor Insurance Policies in Ireland (Public policy or programme) | 85 | On lobbying.ie |
| Sep–Dec 2020 | Hanover Media Strategy Limited | Health | Briefed select parliamentarians on potential Covid-19 vaccine (Public policy or programme) | 22 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Update on potential COVID-19 Vaccine (Matters involving public funds) | 4 | On lobbying.ie |
| May–Aug 2020 | Hanover Media Strategy Limited | Health | Treatment of Irish patients with Amyloidosis in Ireland and reimbursement pathway for Alnylam medicines (Matters involving public funds) | 16 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Transport | The impact of COVID-19 on the tourism sector in Ireland, and the specific impact it is having the Irish car rental industry (Legislation) | 20 | On lobbying.ie |
| Jan–Apr 2020 | Hanover Media Strategy Limited | Health | Optimisation of Rheumatoid Arthritis pathway of care (Matters involving public funds) | 10 | On lobbying.ie |
| May–Aug 2019 | Hanover Media Strategy Limited | Health | The reimbursement process and pathway affecting AstraZeneca medicines & engage government on healthcare innovation (Matters involving public funds) | 15 | On lobbying.ie |
| Jan–Apr 2019 | Hanover Media Strategy Limited | Health | Engaged Government Ministers on patient safety, STEM education and healthcare innovation (Public policy or programme) | 4 | On lobbying.ie |
| Jan–Apr 2018 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndrome (Matters involving public funds) | 12 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Vimizim for Morquio A Syndome (Matters involving public funds) | 16 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Telehealth policy in Ireland (Public policy or programme) | 5 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Funding of Mental Health Organisations (Matters involving public funds) | 5 | On lobbying.ie |
| Sep–Dec 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Public policy or programme) | 16 | On lobbying.ie |
| May–Aug 2017 | Hanover Media Strategy Limited | Health | Telehealth policy in Ireland (Public policy or programme) | 9 | On lobbying.ie |
| Jan–Apr 2017 | Hanover Media Strategy Limited | Health | Reimbursement of Translarna for nonsense mutation Duchenne Muscular Dystrophy (Matters involving public funds) | 19 | On lobbying.ie |
Policy areas in these returns
| Public policy area | Filed returns | Share | Relative to the largest |
|---|---|---|---|
| Health | 36 | 90.0% | |
| Transport | 2 | 5.0% | |
| Children and Youth Affairs | 1 | 2.5% | |
| Sports and Recreation | 1 | 2.5% |